{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-255878","form_type":"8-K","ticker":"RVMD","cik":"0001628171","company_name":"Revolution Medicines, Inc.","filed_at":"2023-10-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.835789+00:00","generated_at":"2026-06-10T00:02:31.542443+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Revolution Medicines reports positive clinical data for RMC-6236 and RMC-6291; selects RMC-5127","bullets":["RMC-6236 shows acceptable safety in 131 patients; common TRAEs include rash (70%) and GI toxicities, mostly Grade 1-2.","RMC-6236 demonstrates dose-dependent exposure and ctDNA reductions across NSCLC, PDAC, and multiple KRAS mutations.","RMC-6291 achieves 50% ORR in NSCLC (prior G12Ci) and 43% in G12Ci-naïve; 40% ORR in CRC with 80% DCR.","RMC-6291 safety includes 25% QTc prolongation (11% Grade 3) but no cardiac sequelae or hepatotoxicity signal.","RMC-5127, an oral covalent tri-complex inhibitor of KRAS G12V (ON), selected as a development candidate."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-255878","json":"https://secwatch.observer/filing/0001193125-23-255878.json","markdown":"https://secwatch.observer/filing/0001193125-23-255878.md","text":"https://secwatch.observer/filing/0001193125-23-255878.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1628171/000119312523255878/0001193125-23-255878-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1628171/000119312523255878/d566894d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T00:02:31.542443+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}